We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK government has revealed that it will increase its funding in UK biotechnology
to over GBP1 billion over the next three years, in a move that could make Britain
one of the best places in the world for science.
British pharma major GlaxoSmithKline Pharmaceuticals is looking at acquiring
brands and companies for an inorganic growth in the country post the product
patent regime that comes into force this year.
Dubai's first pharmaceutical manufacturing company, Globalpharma, announced
the signing of a production licensing agreement with Tiverton Laboratories,
UK.
EU Ambassador to Israel Ramiro Cibrian Uzal said,
"Israel should adopt the highest international standards for protecting
intellectual property rights."
According to Japanese diplomatic sources, the country's government
is keen to explore opportunities in Israel's sophisticated biotech research
and finance sector.
The multinational sector in Mexico has continued to call for a law
to liberalise advertising of drugs, with new legislation on the subject currently
under discussion among lawmakers in the country.
Groups representing Germany's health funds have announced that the
sector posted a EUR4.0bn (US$5.35bn) surplus in 2004, after a EUR2.9bn deficit
in 2003.
Pharmaceutical industry groups in Pakistan have renewed their criticism
of the 2002 Patents Amendment Ordinance, which they claim dilutes the effectiveness
of patent protection terms in the country's 2000 Patents Ordinance.
Dainippon Pharmaceutical and Sumitomo Pharmaceuticals jointly announced the
name, corporate missions and corporate logo of the new company they will establish
on Oct. 1 when they are merged.